{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T23:39:47Z","timestamp":1722814787034},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1038\/s41440-023-01373-0","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T12:02:41Z","timestamp":1689681761000},"page":"2593-2602","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prescription of renin-angiotensin system inhibitors in Japan during the COVID-19 pandemic: interrupted time series study"],"prefix":"10.1038","volume":"46","author":[{"given":"Ryosuke","family":"Miura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"1373_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"1373_CR2","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","volume":"38","author":"M Esler","year":"2020","unstructured":"Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38:781\u20132.","journal-title":"J Hypertens"},{"key":"1373_CR3","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020;382:1653\u20139.","journal-title":"N Engl J Med"},{"key":"1373_CR4","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382:2431\u201340.","journal-title":"N Engl J Med"},{"key":"1373_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ehf2.13744","volume":"9","author":"T Morishita","year":"2022","unstructured":"Morishita T, Takada D, Shin JH, Higuchi T, Kunisawa S, Fushimi K, et al. Effects of the COVID-19 pandemic on heart failure hospitalizations in Japan: interrupted time series analysis. ESC Heart Fail. 2022;9:31\u20138.","journal-title":"ESC Heart Fail"},{"key":"1373_CR6","unstructured":"World Health Organization. International statistical classification of diseases and related health problems 10th revision. 2019. https:\/\/icd.who.int\/browse10\/2019\/en Accessed 16 November 2022."},{"key":"1373_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/ggi.13276","volume":"18","author":"T Ishida","year":"2018","unstructured":"Ishida T, Oh A, Hiroi S, Shimasaki Y, Tsuchihashi T. Current use of antihypertensive drugs in Japanese patients with hypertension: Analysis by age group. Geriatr Gerontol Int. 2018;18:899\u2013906.","journal-title":"Geriatr Gerontol Int"},{"key":"1373_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41440-022-01145-2","volume":"46","author":"C Matsumoto","year":"2023","unstructured":"Matsumoto C, Shibata S, Kishi T, Morimoto S, Mogi M, Yamamoto K, et al. Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19. Hypertens Res. 2023;46:601\u201319.","journal-title":"Hypertens Res"},{"key":"1373_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211\u201320.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1373_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","volume":"27","author":"AK Wagner","year":"2002","unstructured":"Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299\u2013309.","journal-title":"J Clin Pharm Ther"},{"key":"1373_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ekir.2016.12.004","volume":"2","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Thamer M, Kshirsagar O, Zhang Y. Impact of the end stage renal disease prospective payment system on the use of peritoneal dialysis. Kidney Int Rep. 2016;2:350\u20138.","journal-title":"Kidney Int Rep."},{"key":"1373_CR12","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.acap.2013.08.002","volume":"13","author":"RB Penfold","year":"2013","unstructured":"Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013;13:S38\u201344.","journal-title":"Acad Pediatr"},{"key":"1373_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"1373_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41440-019-0238-2","volume":"42","author":"M Ohishi","year":"2019","unstructured":"Ohishi M, Yoshida T, Oh A, Hiroi S, Takeshima T, Otsuka Y, et al. Analysis of antihypertensive treatment using real-world Japanese data-the retrospective study of antihypertensives for lowering blood pressure (REAL) study. Hypertens Res. 2019;42:1057\u201367.","journal-title":"Hypertens Res"},{"key":"1373_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/10641963.2018.1465074","volume":"41","author":"T Ishida","year":"2019","unstructured":"Ishida T, Oh A, Hiroi S, Shimasaki Y, Tsuchihashi T. Current prescription status of antihypertensive drugs in Japanese patients with hypertension: Analysis by type of comorbidities. Clin Exp Hypertens. 2019;41:203\u201310.","journal-title":"Clin Exp Hypertens"},{"key":"1373_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/hr.2016.96","volume":"39","author":"S Hiroi","year":"2016","unstructured":"Hiroi S, Shimasaki Y, Kikuchi T, Otsuka Y, Iwasaki K, Ohishi M. Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data. Hypertens Res. 2016;39:907\u201312.","journal-title":"Hypertens Res"},{"key":"1373_CR17","first-page":"1","volume":"30","author":"Y Nozato","year":"2023","unstructured":"Nozato Y, Yamamoto K, Rakugi H. Hypertension management before and under the COVID-19 pandemic: lessons and future directions. Hypertens Res. 2023;30:1\u20137.","journal-title":"Hypertens Res"},{"key":"1373_CR18","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41440-021-00832-w","volume":"45","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi K, Chin K, Umezawa S, Ito S, Yamamoto H, Nakano S, et al. Influence of stress induced by the first announced state of emergency due to coronavirus disease 2019 on outpatient blood pressure management in Japan. Hypertens Res. 2022;45:675\u201385.","journal-title":"Hypertens Res"},{"key":"1373_CR19","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1253\/circj.CJ-20-0708","volume":"84","author":"H Ishii","year":"2020","unstructured":"Ishii H, Amano T, Yamaji K, Kohsaka S, Yokoi H, Ikari Y. Implementation of percutaneous coronary intervention during the COVID-19 pandemic in Japan - Nationwide Survey Report of the Japanese Association of Cardiovascular Intervention and Therapeutics for Cardiovascular Disease. Circ J. 2020;84:2185\u20139.","journal-title":"Circ J"},{"key":"1373_CR20","first-page":"101116","volume":"43","author":"K Hao","year":"2022","unstructured":"Hao K, Takahashi J, Sato K, Suda A, Sindo T, Godo S, et al. The influence of COVID-19 pandemic on management of acute myocardial infarction in Japan; Insight from the Miyagi AMI Registry Study. Int J Cardiol Heart Vasc. 2022;43:101116.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1373_CR21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","volume":"83","author":"K Kimura","year":"2019","unstructured":"Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83:1085\u2013196.","journal-title":"Circ J"},{"key":"1373_CR22","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"1373_CR23","first-page":"1775","volume":"323","author":"G Onder","year":"2020","unstructured":"Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775\u20136.","journal-title":"JAMA"},{"key":"1373_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fpubh.2020.00152","volume":"8","author":"JM Jin","year":"2020","unstructured":"Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152.","journal-title":"Front Public Health"},{"key":"1373_CR25","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.jinf.2020.04.021","volume":"81","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81:e16\u201325.","journal-title":"J Infect"},{"key":"1373_CR26","doi-asserted-by":"publisher","first-page":"e050938","DOI":"10.1136\/bmjopen-2021-050938.","volume":"11","author":"I Osawa","year":"2021","unstructured":"Osawa I, Goto T, Asami Y, Itoh N, Kaga Y, Yamamoto Y, et al. Physician visits and medication prescriptions for major chronic diseases during the COVID-19 pandemic in Japan: retrospective cohort study. BMJ Open. 2021;11:e050938. https:\/\/doi.org\/10.1136\/bmjopen-2021-050938","journal-title":"BMJ Open"},{"key":"1373_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239\u201342.","journal-title":"JAMA"},{"key":"1373_CR28","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41440-022-00924-1","volume":"45","author":"T Waki","year":"2022","unstructured":"Waki T, Miura K, Tanaka-Mizuno S, Ohya Y, Node K, Itoh H, et al. Prevalence of hypertensive diseases and treated hypertensive patients in Japan: A nationwide administrative claims database study. Hypertens Res. 2022;45:1123\u201333.","journal-title":"Hypertens Res"},{"key":"1373_CR29","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1161\/CIRCULATIONAHA.112.096156","volume":"126","author":"Q Gu","year":"2012","unstructured":"Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126:2105\u201314.","journal-title":"Circulation"},{"key":"1373_CR30","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/jhh.2009.14","volume":"23","author":"A Filippi","year":"2009","unstructured":"Filippi A, Paolini I, Innocenti F, Mazzaglia G, Battaggia A, Brignoli O. Blood pressure control and drug therapy in patients with diagnosed hypertension: a survey in Italian general practice. J Hum Hypertens. 2009;23:758\u201363.","journal-title":"J Hum Hypertens"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01373-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01373-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01373-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:02:35Z","timestamp":1701734555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-023-01373-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1373"],"URL":"https:\/\/doi.org\/10.1038\/s41440-023-01373-0","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"14 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}